Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury

Urology

Volumn 55, Issue 3, 2000, Pages 358-362

  Pannek, Jürgen ^b   Sommerfeld, Hans Jörg ^a   Bötel, Uwe ^a   Senge, Theodor ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERREFLEXIA; KIDNEY DISEASE; MALE; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; SPINAL CORD INJURY; ULTRASOUND; URETHRA PRESSURE; URINALYSIS; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ADOLESCENT; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; SPINAL CORD INJURIES; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 0033963125     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00540-3     Document Type: Article

References (27)

1. Pannek J., Diederichs W., Bötel U. Urodynamically controlled management of spinal cord injury in children. Neurourol Urodyn. 16:1997;285-292.
2. Sauerwein D. Die operative Behandlung der spastischen Blasenlähmung bei Querschnittlähmung. Urologe A. 29:1990;196-203.
3. McGuire E.J., Woodside J.R., Borden T.A., et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 126:1981;205-209.
4. Gerridzen R.G., Thijssen A.M., Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injured patients. J Urol. 147:1992;416-418.
5. Thüroff J.W., Bunke B., Ebner A., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity oxybutynin versus propantheline versus placebo . J Urol. 145:1991;813-817.
6. Madersbacher H., Knoll M. Intravesical application of oxybutinine mode of action in controlling detrusor hyperreflexia . Eur Urol. 28:1995;240-244.
7. Mohler J.L. Relaxation of intestinal bladders by intravesical oxybutynine chloride. Neurourol Urodyn. 9:1990;179-187.
8. Greenfield S.P., Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol. 146:1991;532-534.
9. Massad C.A., Kogan B.A., Trigo-Rocha F.E. The pharmacogenetics of intravesical and oral oxybutynin chloride. J Urol. 148:1992;595-597.
10. Kaplinsky R., Greenfield S., Wan J., et al. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol. 156:1996;753-756.
11. Palmer L.S., Zebold K., Firlit C.F., et al. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 157:1997;638-640.
12. Buyse G., Waldeck K., Verpoorten C., et al. Intravesical oxybutynin for neurogenic bladder dysfunction less systemic side effects due to reduced first pass metabolism . J Urol. 160:1998;892-896.
13. Buyse G., Verpoorten C., Vereecken R., et al. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol. 160:1998;1084-1087.
14. Brendler C.B., Radebaugh L.C., Mohler J.L. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol. 141:1989;1350-1352.
15. Prasad K.V.R., Vaidyanathan S. Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br J Urol. 72:1993;719-722.
16. Hackler R.H. A twenty-five year prospective mortality study in the spinal cord injured patient comparison with the long term living paraplegic . J Urol. 117:1977;486-488.
17. Webb D.R., Fitzpatrick J.M., O'Flynn J.D. A 15-year follow-up of 406 consecutive spinal cord injuries. Br J Urol. 56:1984;614-617.
18. Leng W.W., Blalock H.J., Fredriksson W.H., et al. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol. 161:1999;758-763.
19. Mattiasson A., Ekström B., Andersson K.E. Effects of intravesical instillation of verapamil in patients with detrusor hyperactivity. J Urol. 141:1989;174-177.
20. Madersbacher H., Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia. 29:1991;84-90.
21. Weese D.L., Roskamp D.A., Leach G.E., et al. Intravesical oxybutynin chloride experience with 42 patients . Urology. 41:1993;527-530.
22. Amarenco G., Adba M.A., Kerdraon J. Value of intravesically instilled oxybutynin in refractory bladder hyperactivity. Study of 15 cases. Prog Urol. 2:1992;660-663.
23. Szollar S.M., Lee S.M. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord. 34:1996;284-287.
24. Connor J.P., Betrus G., Fleming P., et al. Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. J Urol. 151:1994;1045-1047.
25. Kasabian N.G., Vlachiotis J.D., Lais A., et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol. 151:1994;944-945.
26. Barrington J.W., Fulford S., Griffiths D., et al. Tumors in bladder remnant after augmentation enterocystoplasty. J Urol. 157:1997;482-485.
27. Lazzeri M., Spinelli M., Beneforti P., et al. Intravesical resinifera toxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol. 32:1998;331-334.